ERBB2 and breast carcinoma: The experimental screening showed a significant dose and time-dependent growth inhibition in HER2-positive breast cancer cells upon treatment with PAMAM dendrimers, mainly G6 cationic PAMAMs, which produced the lowest IC50, thus, indicating a role of PAMAM dendrimers as anti-HER2 compounds.